Worth Venture Partners LLC purchased a new stake in shares of DURECT Co. (NASDAQ:DRRX) in the 2nd quarter, Holdings Channel reports. The fund purchased 264,117 shares of the specialty pharmaceutical company’s stock, valued at approximately $172,000.

Other institutional investors also recently bought and sold shares of the company. Ironwood Investment Management LLC raised its stake in shares of DURECT by 32.0% during the first quarter. Ironwood Investment Management LLC now owns 533,508 shares of the specialty pharmaceutical company’s stock valued at $334,000 after acquiring an additional 129,413 shares in the last quarter. Goelzer Investment Management Inc. bought a new position in DURECT in the second quarter worth approximately $26,000. SG Americas Securities LLC raised its stake in DURECT by 95.0% in the first quarter. SG Americas Securities LLC now owns 274,459 shares of the specialty pharmaceutical company’s stock worth $172,000 after buying an additional 133,714 shares in the last quarter. Acadian Asset Management LLC raised its stake in DURECT by 16.9% in the second quarter. Acadian Asset Management LLC now owns 1,080,352 shares of the specialty pharmaceutical company’s stock worth $705,000 after buying an additional 155,833 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in DURECT by 1,420.0% in the first quarter. BNP Paribas Arbitrage SA now owns 42,545 shares of the specialty pharmaceutical company’s stock worth $27,000 after buying an additional 39,746 shares in the last quarter. 45.28% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:DRRX traded down $0.04 during trading hours on Thursday, reaching $1.90. The company’s stock had a trading volume of 333,497 shares, compared to its average volume of 706,976. The stock has a 50 day moving average price of $1.52 and a two-hundred day moving average price of $0.88. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.92 and a current ratio of 4.26. DURECT Co. has a 12 month low of $0.46 and a 12 month high of $2.00. The company has a market capitalization of $373.32 million, a P/E ratio of -11.88 and a beta of 1.67.

DURECT (NASDAQ:DRRX) last released its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. DURECT had a negative net margin of 123.22% and a negative return on equity of 116.97%. The business had revenue of $3.99 million for the quarter, compared to analyst estimates of $4.05 million. As a group, analysts predict that DURECT Co. will post -0.09 EPS for the current fiscal year.

A number of equities analysts recently commented on DRRX shares. HC Wainwright reissued a “buy” rating and issued a $3.50 price objective on shares of DURECT in a research note on Tuesday, September 10th. Cantor Fitzgerald started coverage on shares of DURECT in a research note on Friday, September 6th. They issued an “overweight” rating and a $5.00 price objective for the company. Stifel Nicolaus boosted their price objective on shares of DURECT from $1.50 to $2.10 and gave the stock a “hold” rating in a research note on Wednesday. Finally, ValuEngine raised shares of DURECT from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.

Read More: How Do I Invest in Dividend Stocks

Want to see what other hedge funds are holding DRRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DURECT Co. (NASDAQ:DRRX).

Institutional Ownership by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.